Skip to content

Study · Measured the body's own peptide · 2017

2 results

Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: A randomized controlled trial.

Nocerino R, Paparo L, Terrin G, Pezzella V, Amoroso A, Cosenza L, Cecere G, De Marco G, Micillo M, Albano F, Nugnes R, Ferri P and 6 more

Show all authors

Ciccarelli G, Giaccio G, Spadaro R, Maddalena Y, Berni Canani F, Berni Canani R

Clinical nutrition (Edinburgh, Scotland)17 Dec 2015Cited by 79 (Europe PMC)

PMID26732025 (opens in a new tab)DOI10.1016/j.clnu.2015.12.004 (opens in a new tab)PepBankPUB-26732025
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In healthy children in daycare, fermented cow's milk or rice raised fecal levels of innate and acquired immunity biomarkers, including the body's own cathelicidin LL‑37, more than placebo.

    In plain wordsIn children, fermented milk or rice raised the body's own gut immune markers, including LL‑37, more than placebo.

    Peptide
    LL-37
    Outcome
    IncreaseFecal innate and acquired immunity biomarkers including LL-37
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    A net increase of all fecal biomarkers of innate and acquired immunity was observed for groups A and B compared to group C.
    2 context sentences
    Summary · context
    Fecal concentrations of innate (α- and β-defensins and cathelicidin LL-37) and acquired immunity biomarkers (secretory IgA) were also evaluated.
    Summary · context
    Prospective randomized, double-blind, placebo-controlled trial (registered under Clinical Trials.gov identifier NCT01909128) on healthy children (aged 12-48 months) consuming daily cow's milk (group A) or rice (group B) fermented with Lactobacillus paracasei CBA L74, or placebo (group C) for three m…

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelRandomized controlled trialOther

    In healthy children in daycare, fecal levels of innate and acquired immunity biomarkers, including the body's own cathelicidin LL‑37, were negatively associated with the occurrence of common infectious diseases.

    In plain wordsIn children, higher levels of the body's own gut immune markers, including LL‑37, were linked to fewer infections.

    Peptide
    LL-37
    Outcome
    Not applicableAssociation of fecal biomarkers with infection occurrence
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Moreover, there was a negative association between fecal biomarkers and the occurrence of CID.
    2 context sentences
    Summary · context
    Fecal concentrations of innate (α- and β-defensins and cathelicidin LL-37) and acquired immunity biomarkers (secretory IgA) were also evaluated.
    Summary · context
    Prospective randomized, double-blind, placebo-controlled trial (registered under Clinical Trials.gov identifier NCT01909128) on healthy children (aged 12-48 months) consuming daily cow's milk (group A) or rice (group B) fermented with Lactobacillus paracasei CBA L74, or placebo (group C) for three m…

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.